These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 15755595)
1. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595 [TBL] [Abstract][Full Text] [Related]
2. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313 [TBL] [Abstract][Full Text] [Related]
3. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593 [TBL] [Abstract][Full Text] [Related]
4. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
5. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594 [TBL] [Abstract][Full Text] [Related]
6. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053 [TBL] [Abstract][Full Text] [Related]
7. Meningococcal surrogates of protection--serum bactericidal antibody activity. Borrow R; Balmer P; Miller E Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600 [TBL] [Abstract][Full Text] [Related]
8. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy. Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S; Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602 [TBL] [Abstract][Full Text] [Related]
10. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400 [TBL] [Abstract][Full Text] [Related]
11. The strategy to control New Zealand's epidemic of group B meningococcal disease. O'Hallahan J; Lennon D; Oster P Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072 [TBL] [Abstract][Full Text] [Related]
12. Recent developments in vaccines to prevent meningococcal serogroup B infections. Vermont CL; van den Dobbelsteen GP; de Groot R Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468 [TBL] [Abstract][Full Text] [Related]
13. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Dyet K; Devoy A; McDowell R; Martin D Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601 [TBL] [Abstract][Full Text] [Related]
14. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881 [TBL] [Abstract][Full Text] [Related]
15. Meningococcal disease: a review on available vaccines and vaccines in development. Bröker M; Fantoni S Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565 [TBL] [Abstract][Full Text] [Related]
16. MeNZB vaccine and epidemic control: when do you stop vaccinating? Loring BJ; Turner N; Petousis-Harris H Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134 [TBL] [Abstract][Full Text] [Related]
17. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040 [TBL] [Abstract][Full Text] [Related]
18. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Gorringe A; Halliwell D; Matheson M; Reddin K; Finney M; Hudson M Vaccine; 2005 Mar; 23(17-18):2210-3. PubMed ID: 15755597 [TBL] [Abstract][Full Text] [Related]
19. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. O'Hallahan J; McNicholas A; Galloway Y; O'Leary E; Roseveare C N Z Med J; 2009 Mar; 122(1291):48-59. PubMed ID: 19322255 [TBL] [Abstract][Full Text] [Related]
20. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845 [No Abstract] [Full Text] [Related] [Next] [New Search]